ライフサイエンスコーパス: post partum

1 ion, and at the post-partum visit (0-14 days post partum).

2 early infant mortality (deaths until 90 days post partum).

3 phone calls after discharge (until 6 months post partum).

4 arget of 50 ng/mL, both during pregnancy and post partum.

5 tosis and are expected to resolve or improve post partum.

6 tum women and women who were not pregnant or post partum.

7 of the nipple can be symptomatic and persist post partum.

8 ed with age in hours over the first few days post partum.

9 estation through planned weaning by 6 months post partum.

10 tionnaire at the last 4 pregnancy visits and post partum.

11 ps were returned to standard laboratory chow post partum.

12 two groups of women at 6 weeks and 6 months post partum.

13 daily, every month from enrolment to 90 days post partum.

14 l, and economic indicators in the first year post partum.

15 to postnatal day 1 and resolution by 2 weeks post partum.

16 nal protocol) from enrollment until 24 hours post partum.

17 mother and baby, but it resolves completely post partum.

18 artum diabetes was excluded at 4 to 16 weeks post partum.

19 e in the maternal circulation for many years post partum.

20 were enrolled a mean (+/-SD) of 16+/-2 days post partum.

21 ctating women were enrolled 5.6+/-0.8 months post partum.

22 group) and were enrolled a mean of 7.9 weeks post partum.

23 or placebo (olive oil) per day until 1 week post partum.

24 tion and 20 weeks' gestation through 42 days post partum.

25 erence and across age groups, pregnancy, and post partum.

26 ays post partum; and 3.31%, within 12 months post partum.

27 nts (77.1% [95% CI, 75.8%-78.3%]) using them post partum.

28 tum, occurring a mean (SD) of 12.5 (14) days post partum.

29 t this discontinuation could lead to relapse post partum.

30 is when diagnosed at 5 to less than 10 years post partum.

31 elopmental delays, at 12, 18, and 24 months' post partum.

32 ventions during home visits at 3 and 8 weeks post partum.

33 s commercial insurance during months 3 to 12 post partum.

34 SUD-related PPR at 42, 90, 180, and 365 days post partum.

35 care use and spending during months 3 to 12 post partum.

36 essment of Health Survey at 12 to 14 months' post partum.

37 ty control condition over the first 16 weeks post partum.

38 m 1994 to 2018 until offspring were 21 years post partum.

39 of gestation and continued through 12 weeks post partum.

40 arin subcutaneously once daily until 6 weeks post partum.

41 mpleted home visits at 1, 3, 8, and 16 weeks post partum.

42 relative to a baseline risk of 12-17 months post partum.

43 alization during pregnancy or within 42 days post partum.

44 t the father's risk of psychiatric treatment post partum.

45 atistical significance was lost at 12 months post partum.

46 efore and after vaccination, at delivery and post partum.

47 ohort of 133 Caucasian infants, three months post partum.

48 rying time of onset throughout pregnancy and post partum.

49 men who received Tdap vaccine within 14 days post partum.

50 study period; 797 of the women were pregnant/post partum.

51 ch are associated with long-term morbidities post partum.

52 150 vs 11 [7%] of 168 pairs; 10.3, 5.4-19.7) post partum.

53 ceptance of proposed services up to 6 weeks' post partum.

54 partum, and for about 75% during months 4-21 post partum.

55 mine than spermidine, except for the 5th day post-partum.

56 followed 100 women with PPCM through 1 year post-partum.

57 ing levels up to 4.41 mumol/l on the 3rd day post-partum.

58 at the 1st, 2nd, 3rd, 4th, 5th and 15th day post-partum.

59 ction at presentation and at 6 and 12 months post-partum.

60 en BM at week 1 (n = 10) and 4 weeks (n = 9) post-partum.

61 ion to delivery and followed for four months post-partum.

62 during pregnancy or in the first four months post-partum.

63 pregnancy but significantly decreased 1 day post-partum.

64 of the nascent epithelium at the forth week post-partum.

65 easome were restored to normal levels 7 days post-partum.

66 Moreover, PlGF levels fell by 83% on day 1-2 post-partum.

67 abnormalities and died between 7 and 21 days post-partum.

68 ripheral vein on the same day and second day post-partum.

69 stein cows at milkings 1, 2, 3, 4, 8, and 14 post-partum.

70 isks for CVD complications in the first year post-partum.

71 nian ewes were enrolled between 7 +/- 3 days post-partum.

72 the catchment area for follow-up of 28 days post-partum.

73 al admissions for the child within 24 months post-partum.

74 raphy at baseline and at 2, 6, and 12 months post-partum.

75 after 16 weeks' gestation and before 7 days post partum; 0.86 [0.74-1.00], p=0.039), early preterm d

76 100; breastfeeding status at 4.5 to 6 months post-partum: 12.5% exclusive, 21.4% almost exclusive, 60

77 2]; I2 = 85.0%; 15 studies [n = 41 054]) and post partum (15.7% vs 9.6%; aOR, 1.51 [95% CI, 1.40-1.70

78 (E17-19, 173.7 %) fetal and neonatal (1 day post partum, 161 %) TG+ compared with transgenic negativ

79 At 6 weeks' post partum, 174 participants in the intervention group

80 efavirenz (EFV)-containing ART until 2 weeks post-partum (2wPP), between 9th March 2017 and 16th Janu

81 men had HIV-1 RNA data available at 50 weeks post partum: 366 (96%) in the dolutegravir-containing gr

82 of 10 events in the pregnancy group occurred post partum (4 CeADs and 1 stroke).

83 More episodes began post partum (40.1%), followed by during pregnancy (33.4%

84 tihypertensive medication use within 2 years post partum (5 postpartum time intervals) by HDP status

85 ove prepregnancy weight, 7.8 kg; mean months post partum, 5.2 months) randomized to the intervention

86 ation) and late (32-36 weeks) pregnancy, and post-partum (6-10 weeks after delivery).

87 ng antiretroviral treatment 6 months or more post partum (7.8% and 12.0%, respectively; P=0.39).

88 da dairy ewes were enrolled in the immediate post-partum (7 +/- 3 days in milk) and divided into two

89 and 32 (32.0%) between 24 hours and 6 weeks post partum; 79 (79.0%) had obesity, 61 (61.0%) had publ

90 By 32 weeks post partum, 96% of women in the intervention groups and

91 At 42 days post partum, a major depressive episode was observed in

92 this population most likely to benefit from post-partum adherence interventions.

93 mL (95% CI 0.5 to 1.0) in the first 12 weeks post partum after 104 livebirths, and subsequently stabi

94 all-cause neonatal mortality within 28 days post-partum among babies who survived the first 24 h of

95 rson-years in women who were not pregnant or post partum and 11.8 (8.4-15.3) per 1000 person-years in

96 who were currently pregnant or up to 1 year post partum and 19 health care workers (eg, physicians,

97 18.9-22.4) in women who were not pregnant or post partum and 8.2 (5.7-11.8) in pregnant or post-partu

98 sessed in mothers and infants until 24 weeks post partum and analysed in all participants who receive

99 Plasma samples were obtained 10 days post partum and analyzed for resistance mutations.

100 t normal elastic fibers in the uterine tract post partum and develop pelvic organ prolapse, enlarged

101 eding and any infant formula use at 24 weeks post partum and time to breastfeeding cessation.

102 essed included retention in care at 6 weeks' post partum and uptake of PMTCT services, measured by at

103 All pre-eclampsia-related deaths were post-partum and 50% were due to heart failure.

104 all-cause neonatal mortality within 28 days post-partum and all-cause neonatal mortality within 28 d

105 the hyaloid vessels are persistent at 8 days post-partum and the retinal vasculature overgrows.

106 pubertal development (between days 23 and 30 post partum) and independently of the presence of testos

107 during pregnancy, 21 (21.0%) within 24 hours post partum, and 32 (32.0%) between 24 hours and 6 weeks

108 ing pregnancy, for 66% in the first 3 months post partum, and for about 75% during months 4-21 post p

109 men with a second pregnancy within 24 months post-partum, and emergency attendances and hospital admi

110 80% enrollment through pregnancy to 60 days post partum; and (3) evidence of coverage for depression

111 n the prenatal period; 1.14%, within 60 days post partum; and 3.31%, within 12 months post partum.

112 urodevelopmental outcomes of ante-partum and post-partum antiretroviral exposure in HIV-exposed and u

113 rigin persistent in the maternal circulation post-partum are associated with protection against invas

114 nts retained in care at 6 weeks and 12 weeks post partum (assessed by generalised linear mixed effect

115 who were aged 10 to 50 years and pregnant or post partum at death (collectively, the perinatal group)

116 ple sclerosis stability during pregnancy and post partum, balanced with fetal and newborn safety.

117 m 183 days prior to delivery through 28 days post partum (baseline).

118 abase to compare follow-up in the first year post partum between individuals with GD, type 2 diabetes

119 lent to oxytocin when used to stop excessive post-partum bleeding suspected to be due to uterine aton

120 creases major depressive episodes at 42 days post partum by about three quarters.

121 visits were made during pregnancy and early post partum by peer counsellors recruited from the same

122 infection during pregnancy or up to 6 weeks post partum by positive nucleic acid or antigen test, an

123 women were offered screening at 4 to 6 weeks post partum by telephone.

124 Three had myocarditis, 4 had post-partum cardiomyopathy (PPCM), and 1 had idiopathic

125 result of self-test distribution: two in the post-partum care group and two female sex workers.

126 were enrolled (61 in antenatal care, 117 in post-partum care, and 102 female sex workers); follow-up

127 cipants in antenatal care, two (2%) of 91 in post-partum care, and 41 (14%) of 298 from female sex wo

128 of 53 in antenatal care, 62 (68%) of 91 from post-partum care, and 53 (83%) of 64 female sex workers.

129 ipants in antenatal care, 91 (86%) of 106 in post-partum care, and 64 (75%) of 85 female sex workers.

130 prepregnancy, antenatal, labour, birth, and post-partum care, and family planning.

131 ction of weather metrics, to assess pre- and post-partum climatic influences on survival on herds in

132 Kenya: a health facility with antenatal and post-partum clinics and a drop-in centre for female sex

133 B-myb expression decreases at day 18 post partum, coincident with the initial appearance of l

134 vely had a relapse within the first 6 months post partum compared with 29 women (24.2%) who intended

135 ficantly reduced depression levels 12 months post partum compared with a control.

136 n increased stroke risk during pregnancy and post partum compared with their nonpregnant contemporari

137 protective for the child, and when continued post partum, could enhance the quality of caregiving for

138 Depression within 12 months post partum, defined as filling an antidepressant prescr

139 red further prescriptions more than 3 months post partum, depending on HDP status and antenatal medic

140 tients (</=6 months post partum) with severe post-partum depression (Hamilton Rating Scale for Depres

141 who took paternity leave had reduced odds of post-partum depression (OR 0.74 [95% CI 0.70-0.78]) as d

142 Post-partum depression is a serious mood disorder in wom

143 nvestigation of brexanolone in patients with post-partum depression is in progress.

144 For mothers, the prevalence of post-partum depression was 16.1% among those whose partn

145 INTERPRETATION: In women with severe post-partum depression, infusion of brexanolone resulted

146 ave might place mothers at a greater risk of post-partum depression, suggesting that optimal length a

147 acid (GABAA) receptors, for the treatment of post-partum depression.

148 e development of therapies for patients with post-partum depression.

149 nal and caesarean deliveries, from triage to post-partum discharge) and breast cancer care (diagnosis

150 Transcription ceases in the ovary by 3 days post partum (dpp), but continues in the testis through a

151 he height in meters] of 25 to 30) at 4 weeks post partum either to restrict their energy intake by 50

152 isease is more common in women than men, and post partum exacerbation of thyroiditis is common.

153 At 3 months post partum, exclusive breastfeeding was practised by 67

154 st report of persistent Y chromosomal DNA in post-partum female dogs and these results suggest that f

155 At the 5-year post-partum follow-up, we applied an untargeted approach

156 detectable in blood samples obtained 10 days post partum from 32 percent of the women who had receive

157 In this pilot study on umbilical cords post partum from healthy non-obese (BMI = 19-25; n = 7)

158 followed up from pregnancy through 12 months post partum from June 27, 2016, to December 9, 2019.

159 Post-partum GD3 is not highly expressed in the brain.

160 l status, marriage type, whether pregnant or post partum, gestational age (if pregnant), and HIV risk

161 A2, mortality in the 5 to less than 10 years post partum group was significantly increased, but only

162 nly 32% of 244 women followed to four months post-partum had attended an HIV clinic and been assessed

163 tum haemorrhage (1.49, 1.01-2.20; I(2)=37%), post-partum haemorrhage (1.29, 1.13-1.49; I(2)=41%), hyp

164 d antibiotics to reduce maternal deaths from post-partum haemorrhage and sepsis could be a highly eff

165 timates from published work of occurrence of post-partum haemorrhage and sepsis, case fatality, and t

166 978 (10%) women were diagnosed with primary post-partum haemorrhage and were randomly assigned to re

167 809 (3%) women were diagnosed with post-partum haemorrhage and were randomly assigned to re

168 ous to intravenous oxytocin for treatment of post-partum haemorrhage in women not exposed to oxytocin

169 ior to intravenous oxytocin for treatment of post-partum haemorrhage in women receiving prophylactic

170 he key events leading to maternal death from post-partum haemorrhage or sepsis after delivery.

171 estimated that of 2860 maternal deaths from post-partum haemorrhage or sepsis per year in Malawi, in

172 ning, could reduce maternal mortality due to post-partum haemorrhage or sepsis.

173 Deaths from post-partum haemorrhage peaked 2-3 h after childbirth.

174 on of women in the placebo group with severe post-partum haemorrhage than those in the cholecalcifero

175 acid in acute severe bleeding (traumatic and post-partum haemorrhage).

176 For coverage of uterotonics to prevent post-partum haemorrhage, early initiation of breastfeedi

177 tocin, the standard of care for treatment of post-partum haemorrhage, is not available in all setting

178 Oxytocin, the gold-standard treatment for post-partum haemorrhage, needs refrigeration, intravenou

179 uitable first-line treatment alternative for post-partum haemorrhage.

180 Retained placenta is associated with post-partum haemorrhage.

181 ics reduce death from bleeding in trauma and post-partum haemorrhage.

182 mental and caesarean births, infections, and post-partum haemorrhage.

183 labour and delivery, and are more at risk of post-partum haemorrhage.

184 in view of its relevance in time-to-death in post-partum haemorrhage.

185 is increasingly used ad hoc for treatment of post-partum haemorrhage; however, evidence is insufficie

186 Maternal depression (antepartum or post partum) has been linked to negative health-related

187 IUD insertion and insertion within 36 weeks post partum have been associated with increased risk of

188 erine and intrapartum MTCT, whereas maternal post-partum HIV acquisition, untreated maternal HIV, and

189 s in pregnancy, neonatal thyrotoxicosis, and post-partum hyperthyroidism.

190 The lesions persisted post partum in 22 patients (88%).

191 NVP resistance mutations at day 10 or week 6 post partum in each arm was compared with that of a hist

192 ately 0.5 kg per week between 4 and 14 weeks post partum in overweight women who are exclusively brea

193 008, to June 30, 2012, with 1 year follow-up post partum in the nationwide German MS and pregnancy re

194 loped a median (IQR) of 5.1 (0.7-10.6) years post partum in those with HDP and 10.6 (4.2-15.8) years

195 in those with HDP and 10.6 (4.2-15.8) years post partum in those with normotensive first pregnancies

196 th and 28th week of pregnancy and 3-6 months post-partum in a cohort of obese and normal-weight pregn

197 ntive intervention or not, over 1 or 5 years post partum, in a variety of scenarios, including varyin

198 EP implementation arise during pregnancy and post partum, including the integration of provider train

199 Additional studies are needed to examine the post-partum increase in viremia.

200 At 16 weeks post partum, infants in the RP group had longer reported

201 At 2 weeks post partum, initial intervention materials appropriate

202 with IUD insertion 4 days to 6 weeks or less post partum is nearly seven times that of insertion non-

203 Adjusted HRs using women with non-post partum IUD insertion as the referent were 5.34 (95%

204 At 1 day post-partum, lactationally active, distended lobuloalveo

205 the pro-inflammatory microenvironment during post-partum mammary involution promotes parity-associate

206 ral phenotypes of EL mice are dependent upon post-partum maternal care which if systematically enhanc

207 ing practices were observed through 9 months post partum (mean [SE], 3.48 [0.07] in the intervention

208 n 31 mother-infant dyads within the first 15 post-partum months utilizing peptide microarray.

209 From 42 days to 4 months post partum, mortality was still 1.20 (1.03-1.39) times

210 At 6 months post-partum, mothers were asked if they had experienced

211 (n22) and repeated during lactation 12 weeks post-partum (n14) and twice in NPNL women (n23 and n10,

212 ster, and 11 in the third trimester; 12 were post partum, occurring a mean (SD) of 12.5 (14) days pos

213 Nine women died between 2 weeks and 48 weeks post partum (one in maternal-antiretroviral group, two i

214 emerged as prominent symptom dimensions with post-partum onset and were notably severe.

215 ternal complications occurring up to 6 weeks post partum or until hospital discharge, whichever was l

216 Small studies reported poor post-partum outcomes among young women living with perin

217 (p = 0.001), and presentation after 6 weeks post-partum (p = 0.02) were associated with a lower LVEF

218 e immediately after birth (P0) or at 10 days post partum (P10) to determine whether neural responses

219 acute neurological symptoms in pregnant and post-partum patients is likely to improve as we learn mo

220 is nearly seven times that of insertion non-post partum, perforation remains an incredibly rare even

221 hyperthyroidism in pregnancy and during the post-partum period are special circumstances that need c

222 associated with HIV during pregnancy and the post-partum period in sub-Saharan Africa.

223 The post-partum period represents an important opportunity t

224 severe mental disorders in pregnancy and the post-partum period.

225 en died, 235 of them during pregnancy or the post-partum period.

226 breastfeeding and history of low mood in the post-partum period.

227 that developed in the intrapartum and early post-partum period.

228 s in childhood, during pregnancy, and in the post-partum period.

229 he decrease in eGFR persisted into the early post-partum period.

230 diagnosed with eclampsia, especially in the post-partum period.

231 reful attention throughout pregnancy and the post-partum period.

232 inatal depression (ie, during antepartum and post-partum periods) among women residing in low-income

233 occurs endogenously during pre-menstrual and post-partum periods, when decreased response to BDZ has

234 intervention should include preconception or post-partum periods.

235 of symptom onset within pregnancy and three post-partum periods.

236 Pregnant or post-partum person-years were calculated for HIV-infecte

237 ral exposure during both the ante-partum and post-partum phases did not result in greater development

238 tained within their assigned ante-partum and post-partum phases throughout their treatment arm period

239 port use across preconception, pregnancy and post-partum phases.

240 stage, ii) late pregnant (LP), iii) one day post-partum (PP1) and iv) 7 days post-partum (PP7).

241 ii) one day post-partum (PP1) and iv) 7 days post-partum (PP7).

242 threshold up to 4 months would increase the post-partum pregnancy-related mortality ratio by 40%.

243 e available during pregnancy and immediately post partum, pregnancy-related loss of maternal renal fu

244 By 5 days post-partum, prominent expression became restricted to m

245 and those with the onset of new episodes of post-partum psychosis.

246 ression was significantly increased by day 1 post partum, reaching levels greater than those normally

247 ens of HAART from pregnancy through 6 months post partum resulted in high rates of virologic suppress

248 For six post-partum risk intervals (0-1 days, 2-6 days, 7-13 day

249 ages should reflect the extended duration of post-partum risk.

250 sequently stabilised from 13 weeks to 1 year post partum (slope -0.01 log(10) copies per mL, 95% CI -

251 he full cohort and 94 817 individuals in the post-partum subcohort were analysed.

252 Women with sustained post-partum suppression were older at conception (22.9 y

253 Post-partum surgical complications and prolonged hospita

254 thdrawal paradigm, designed to mimic PMS and post-partum syndrome in a rat model.

255 Post partum, the mother-infant pairs were randomly assig

256 xpression of milk proteins, and by two weeks post-partum their pups are smaller in size.

257 tained from the mothers weekly until 4 weeks post partum then monthly.

258 Extending the WHO 42-day post-partum threshold up to 4 months would increase the

259 dies; however, whether treatment can prevent post-partum thyroiditis in women who are or have been an

260 Post-partum thyroiditis is substantially more frequent i

261 Post-partum thyroiditis occurs in 5-10% of women, and ma

262 d their newborns weekly for up to 3-6 months post-partum, to document cases of acute respiratory illn

263 reatment throughout both the ante-partum and post-partum treatment phases (adjusted means 80.64 [95%

264 antiretrovirals in both the ante-partum and post-partum treatment phases were similar to those for c

265 filled a prescription in the first 3 months post partum, up to 55.9% (95% CI, 46.2%-66.1%) required

266 e objective of this study was to monitor the post-partum variation of polyamine content, in ovine and

267 aemia (20.4 years, 18.8-22.2), or persistent post-partum viraemia (19.0 years, 17.7-20.5).

268 uppression were also strong risk factors for post-partum viraemia.

269 perinatal HIV infection have a high risk of post-partum viraemia.

270 ify women in this population at risk of poor post-partum virological control.

271 itiation, at 36 weeks' gestation, and at the post-partum visit (0-14 days post partum).

272 tients were lost to follow-up, and the final post-partum visit was on Aug 6, 2020.36 (9%) of 399 part

273 d of less than 50 copies per mL at the first post-partum visit, and the primary safety outcome was th

274 erse events in mothers and infants until the post-partum visit.

275 odifying therapy reinitiation within 1 month post partum was associated with lower odds of early post

276 ver, the relapse rate ratio during 12 months post partum was lower (0.49; 95% CI, 0.28-0.86) when nat

277 al contraceptive initiation within 12 months post partum was treated as a time-varying exposure.

278 maternal mood between delivery and 6 months post-partum was associated with an increased risk of inf

279 of blood glucose, and increased attention to post-partum weight management.

280 on depression rating scale scores at 42 days post partum were also lower in the esketamine group (-4,

281 occurring during pregnancy and up to 42 days post partum were defined as pregnancy related.

282 bsolute risks of depression within 12 months post partum were estimated using Cox proportional hazard

283 nown HIV status who died during pregnancy or post partum were HIV infected.

284 During farm visits, cows within 21 days post-partum were categorized in one of three clinical pr

285 All women were followed up for 24 weeks post partum, when they completed an exit questionnaire t

286 0 and an LVEDD >/=6.0 cm recovered by 1 year post-partum, whereas 91% with both a baseline LVEF >/=0.

287 Continued evaluation at 1, 2, and 3 years post partum will be conducted to assess the long-term ou

288 cian-referred female inpatients (</=6 months post partum) with severe post-partum depression (Hamilto

289 ected data prospectively for all pregnant or post-partum women admitted to the obstetric department.

290 able rates were compared between pregnant or post-partum women and women who were not pregnant or pos

291 ct that roughly 24% of deaths in pregnant or post-partum women are attributable to HIV in sub-Saharan

292 Acute neurological symptoms in pregnant and post-partum women could be caused by exacerbation of a p

293 HIV-infected pregnant or post-partum women had around eight times higher mortalit

294 PrEP implementation for pregnant and post-partum women lags behind implementation for other h

295 , 2017, and June 13, 2018, 9376 pregnant and post-partum women were assessed for behavioural risk fac

296 ed on tenofovir to HIV-negative pregnant and post-partum women with a substantial risk of HIV acquisi

297 4-15.3) per 1000 person-years in pregnant or post-partum women.

298 ion to the needs of HIV-infected pregnant or post-partum women.

299 ost partum and 8.2 (5.7-11.8) in pregnant or post-partum women.

300 fy viral load trajectory groups in the first post-partum year after livebirths.